TOP Vision

TO Pharma ("TOP") seeks to make a positive difference in people's lives by becoming a leading global clinical pharmaceutical company focused on the commercializing of cannabinoid-based therapies in FDA-regulated clinical indications and in selected OTC markets.

Tikun Olam Partnership

TOP has partnered with Tikun Olam to rapidly identify and efficiently advance cannabinoid development programs that have strong intellectual property protection, address important markets of unmet need with a focus on orphan indications, and offer expedited paths to human clinical testing.

Target Markets

Seeking To Become A Leading Provider Of Cannabinoid-Based Pharmaceuticals For Multiple Indications For Which The Company’s Proprietary Products Have Shown Promise In Preventing & Treating Disease

Estimated Market Size

Chron's Disease

Global therapeutics market size is expected to reach USD $4.7 billion by 2025.


Global Alzheimer's therapeutics market is expected to reach $6.4 billion by 2024.


The US hemp derived non-pharmaceutical CBD market may reach up to $1.3 Billion by 2022 of which patches will be a portion.